Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Lung Neoplasms 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Melanoma 1Lymphoma 1Hematologic Neoplasms 1Glioma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Acrocephalosyndactylia 1

Interventions

pembrolizumab 24Magnetic Resonance Spectroscopy 10Carboplatin 8Nivolumab 7Docetaxel 7Paclitaxel 6Gemcitabine 6Trastuzumab 5Taxes 5Injections 5Fluorouracil 5Fluorodeoxyglucose F18 5Drug Therapy 5Cyclophosphamide 5Cisplatin 5fludarabine 4X-Rays 4Specimen Handling 4Radiotherapy 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Leucovorin 4durvalumab 3atezolizumab 3Surveys and Questionnaires 3Standard of Care 3Irinotecan 3Immunohistochemistry 3Gene Expression Profiling 3Early Intervention, Educational 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Esophageal Neoplasms × erdafitinib × Thoracic × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02699606 2025-04-27

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

Janssen Research & Development, LLC

Phase 2 Completed
35 enrolled
GastrointestinalThoracic

Acrocephalosyndactylia, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡